Starpharma Holdings Ltd has released a press release.
DEP outperforms Gemzar in human pancreatic cancer model
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- FDA Authorises Clinical Trial with AstraZeneca DEP product
- DEP irinotecan synergistic with Lynparza in refractory model
- VivaGel BV regulatory approvals continue in Asia
- Positive results with Targeted DEP using antibody fragment
- Promising efficacy signals observed in ongoing DEP trials
Later from Starpharma
- UK launch of VivaGel BV
- VivaGel condom receives regulatory approval in Europe
- AGM - Chairman address and CEO presentation
- DEP cabazitaxel progresses to phase 2 on positive results
- Starpharma receives $4.9M R&D tax incentive refund
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma